Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
Overview
After months of sideways price action, Gilead Sciences (NASDAQ: GILD) has started zooming higher. This comes on the heels of the pharmaceutical company's latest quarterly earnings release.
Trading around $130 per share ahead of earnings, the stock has since surged to around $146 per share. Further upside may be in the cards, mostly due to the key factor driving its post-earnings rally.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.